We present the case of an 11-year-old boy who suffered from an undefined tic disorder and incidentally sustained a traumatic fracture of the clavicle. The fracture healing course was complicated by the tic activity, and the frequency and intensity of the tics were worsened by the presence of clavicular pain. He underwent surgery and his management required the collaboration of orthopaedic surgeons, the Acute Pain Service, neurologists for tic management and rehabilitation physicians who performed the intramuscular injections of botulinum toxin. We recommend a multidisciplinary and multimodal approach to managing patients suffering from tic disorders and highlight the consideration of intramuscular injections of botulinum toxin, which were successful for this patient.
A tic is a repetitive involuntary movement or sound that is often preceded by premonitory sensations or urges. Motor or vocal tics can be single repetitive jerks or inarticulate sounds (simple tics), in contrast to the co-ordinated actions of complex tics that may resemble purposeful movements or partial phrases. The severity of tic activity varies between individuals, as well as over the course of time in relation to specific triggers, such as psychosocial stressors, certain drugs or infections. We describe a paediatric case where a tic disorder was exacerbated by a traumatic fracture of the clavicle and fracture displacement occurred secondary to the tic disorder. Despite optimising pharmacological therapy to treat the pain and tic activity, intramuscular injections of botulinum toxin were required to control the problematic tic activity.
CASE HISTORY
Parental consent was obtained on behalf of the patient prior to submitting this case report for publication.
An 11-year-old boy weighing 58 kg presented to a tertiary paediatric hospital having sustained an isolated left clavicular fracture after two mechanical falls a few weeks prior. His medical history was unremarkable, except for the presence of motor tic activity, for which he was awaiting a neurological opinion. The tics were described as slow rhythmical writhing movements, predominantly involving his neck and shoulder muscles, but also extending into his trunk. The tics had been occurring intermittently over the previous three years with the main symptom being neck pain. However, it had been managed without pharmacological treatment and did not interfere greatly with his daily activities prior to the development of the traumatic fracture. Subsequently, the tics worsened in frequency and intensity, causing increased pain and distress.
His clavicular fracture was initially managed conservatively by the local family practitioner with a supportive sling. However, follow-up X-rays showed a non-uniting fracture, attributed to movement of the fracture site secondary to exacerbation of his tic activity. He was subsequently referred to the orthopaedic team and underwent an open reduction and internal fixation of the fracture uneventfully, and was prescribed multimodal analgesia including a morphine patient-controlled analgesia device.
Postoperatively, pain and tic control were difficult to achieve with each exacerbating the other. This culminated in the development of a wound haematoma and dehiscence two days postoperatively, requiring a second operation for haematoma evacuation and re-suturing of the wound.
Analgesia was managed by our Acute Pain Service, initially with morphine patient-controlled analgesia (1 mg bolus, five-minute lockout time) and subsequently with a morphine infusion as the patient was unable to use patient-controlled analgesia Y. Chen, P. ThalaYasingam Anaesthesia and Intensive Care, Vol. 38, No. 6, November 2010 effectively. The morphine infusion was commenced at approximately 50 µg/kg/hour and increased to 80 µg/kg/hour, titrated to his escalating pain. A ketamine infusion (0.2 mg/kg/hour) was briefly trialled as adjuvant analgesia, but was abandoned due to hallucinations, nightmares and dysaesthesia in his lower limbs. Simple analgesics (paracetamol, ibuprofen and tramadol) were also regularly administered.
Tic activity was managed primarily by the neurology team with sequential trials of numerous drugs over the week, including diazepam 2.5 mg as required up to three times per day, tetrabenazine 12.5 mg twice a day, clonidine 150 µg three times a day and risperidone 0.5 mg twice a day. Unfortunately none of these medications was effective except for a modest reduction in the frequency and intensity of the tic activity with risperidone and tetrabenazine. His pain remained uncontrolled despite maximum levels of opioid and adjuvant therapy.
On day six after his initial operation, botulinum toxin (BONT) injection was suggested by the neurology team and subsequently performed by the rehabilitation physician on the ward with ultrasound guidance and an electrical stimulator used to aid muscle identification. The muscles contributing to tic activity were injected with BONT-A (Allergan, Gordon, NSW): pectoralis major (60 units), anterior deltoid (40 units), trapezius (50 units) and levator scapulae (30 units). The procedure was uncomplicated and was well-tolerated by the patient with nurse-initiated boluses of morphine. His tic activity diminished substantially within the first 24 hours following BONT injections. His pain significantly improved, enabling his morphine infusion to be weaned over the next 48 hours. He was discharged home five days after the BONT injections with a weaning regimen of risperidone.
The BONT-induced muscle paralysis was effective for three to four months. This allowed the fracture to unite solidly in a good position. However, his tics returned along with clavicular pain of uncertain cause. This has required the re-introduction of risperidone and tetrabenazine therapy with a plan to repeat the intramuscular BONT injections and consideration given to removing the metal work from the clavicle.
DISCUSSION
Tic disorders can be classified as primary or secondary. Tourette's syndrome is the archetypal primary tic disorder where both motor and vocal tics are present from childhood lasting for at least one year, and are fluctuating in nature. Other primary tic disorders include chronic motor or vocal tic disorders and transient tic disorder when the tics last less than one year. Secondary tic disorders can be due to any disease process that affects the central nervous system, including infection, trauma, ischaemia, infiltrative and accumulative disorders. In addition, drugs may cause tics, such as neurolepticinduced tardive dyskinesia, some anticonvulsants, caffeine and other stimulants.
The management of patients with tics involves a comprehensive, multidisciplinary approach that focuses not only on treating the tic, but also the commonly associated neuropsychiatric comorbidities (namely, attention deficit hyperactivity disorder and obsessive compulsive disorder) and concurrent psychosocial stressors which may worsen tic activity. The latter two involve psychiatric intervention with patient and family education, counselling, cognitivebehavioural therapy and drug therapy 1 .
Treatment of tics can be difficult and involves identifying problematic tics affecting daily functioning that may benefit from pharmacological therapy. Drugs shown to have tic-suppressant activity include alpha-2-agonists (clonidine), benzodiazepines (clonazepam), dopamine antagonists (haloperidol, pimozide), dopamine-depleting drugs (tetrabenazine) and some antipsychotics agents (risperidone, olanzepine). Commencement of drug therapy warrants an individual risk-benefit assessment as they have known undesirable sideeffects including sedation, depression and mental dulling. Additionally, utilisation of the minimum dose of a drug to enable daily functioning is the goal of therapy, rather than tic cessation.
Local injection of BONT causes transient muscle paralysis through antagonism at the cholinergic neuromuscular junction and is an excellent option when only a few tics are the cause of significant disruption in the patient's life. BONT has been gradually emerging as an effective treatment for dystonic disorders. It is particularly useful in the management of cervical dystonia which may be primary or secondary to another disorder, commonly Tourette's syndrome or cerebral palsy. There are numerous small studies and a few systematic reviews which have supported the safety and efficacy of BONT injections as a first-line option in the treatment of cervical dystonia 2-5 which if left untreated, may lead to progressive cervical myeloradiculopathy.
The current literature on the use of BONT in managing tic disorders is limited to a handful of case reports 6, 7 or case series 8, 9 and a single small randomised control trial 10 . These studies have addressed patients with vocal tics, ear-wiggling tics or tics of the neck muscles that were idiopathic in nature or associated with Tourette's syndrome. Collectively, the effectiveness and safety of BONT in reducing tic frequency and relieving the premonitory symptoms associated with tic disorders was supported by all studies. Indeed, one case report even recorded complete resolution of violent dystonic tics of the neck following aggressive treatment with BONT and neuroleptic medication in a patient suffering from Tourette's syndrome complicated by tetraparesis and cervical myelopathy 11 . The literature on BONT in tic disorders in the perioperative setting is scant, limited to case reports that discuss the use of intramuscular BONT injections perioperatively to facilitate immobilisation, stabilisation and postoperative recovery after cervical fusion in patients with cervical dystonia or tics causing serious cervical spine disease 12 .
The benefit of intramuscular BONT injections has been reported to last two to 20 weeks. In up to 5% of patients who receive regular BONT injections, neutralising antibodies develop, resulting in shorter intervals between 'booster' injections and necessitating higher doses of BONT being required. Botulinum toxin A is the most commonly studied and injected form of BONT, but botulinum toxin B is an alternative, particularly in patients where neutralising antibodies are present 13 .
Further research is required to fully define the role of BONT in the short-and long-term management of movement disorders, with the current evidence suggesting BONT as a treatment option for motor tics (Level C) and cervical dystonia (Level A) 14 . As such, careful consideration of the risk-benefit of performing BONT injections needs to be undertaken for each patient, with the expertise of a neurologist or rehabilitative physician.
In conclusion, patients with a tic disorder who have suffered trauma should be managed using a multidisciplinary approach in the perioperative setting. This includes involving the neurology team and rehabilitation physicians early, in order to facilitate pharmacological control of tic activity. This will aid in healing and recovery from the injury. BONT should be considered as a useful adjunct in tic management for both short-and long-term settings. However, this should be administered under the care of specialist neurology or rehabilitation physician teams.
